呼吸系统疾病用药专栏
XU Shu;LI Jing;DU Junxian
2013, 32(3): 316-318.
ABSTRACT Objective To evaluate the shortterm relief and longterm control of acute moderate asthma in adult patients by atorvastatin.MethodsA total of 80 adult patients with acute moderate asthma were randomly divided into treatment and control groups, 40 cases in each. Both groups were administrated with fluticasone/salmeterol composite dry powder inhaler at the dose of 250 μg/50 μg twice a day in the acute phase and once daily in remission. The treatment group was also given 40 mg atorvastatin for the first day, followed by 20 mg daily for long term maintenance. We observed asthma symptoms, wheezing disappearance, length of hospital stay, forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), asthma control level within the following 3 months as well as adverse events in the two experimental groups.ResultsThe duration of asthma remission, wheezing disappearance, and length of hospital stay (4.60±0.18,5.28±0.18,and 7.50±0.20 d, respectively) in the treatment group were shorter than those (5.52±0.20,6.45±0.23,and 8.63±0.20 d, respectively) in the control group (P<0.01). The experimental group had significantly better improvements of FEV1 (0.312±0.076 vs. 0.276±0.069 L,P<0.05) and PEF (52.6±10.8 vs. 42.6±11.5 mL·min-1, P<0.01) as compared to the control group. Asthma control within 3 months in the experimental group was better than that of the control group(92.5% vs. 70.0%,P<0.05). The two groups presented similar safety profile.ConclusionAstorvastatin is safe and effective for relieving symptoms of acute phase and the providing long term management of the disease in adult patients with asthma.